Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

New ACC/AHA dyslipidemia treatment guidelines say prescribers should consider LDL cholesterol-lowering drugs’ costs, but Amgen and Esperion note the work they’ve done to ensure access to their products.

Newly published guidelines for treating dyslipidemia recommend testing for Lipoprotein(a), a cardiovascular disease risk factor with no treatments, but with multiple candidates in the clinic.

Scrip spoke with Debiopharm’s Luke Piggott about the Swiss biotech’s interest in synthetic lethality and strategy around development and partnering.

The German biotech hopes to start Phase IIb trials soon of the oral complement C5a inhibitor in the extremely competitive hidradenitis suppurativa market.

Underwhelming efficacy led to the myostatin inhibitor's discontinuation of in SMA and FSHD, but Roche will continue a separate study in obesity. Meanwhile, Scholar Rock’s rival apitegromab could soon be back on track for approval.